2007/001 NICE response to judicial review proceedings

Commenting of the application for judicial review by Eisai Limited, supported by their co-promotion partner Pfizer Limited, of the process by which NICE developed guidance on the use of drugs for treating Alzheimer's disease, Andrew Dillon, Chief Executive of NICE, said:

“We are disappointed that Eisai Limited have taken this step. We consider their claim without foundation and it will require us to divert energy and funding from the work we do to support patients and health professionals and get the most out of the resources available to the NHS."